Antibe Therapeutics Company Profile (CVE:ATE)

About Antibe Therapeutics (CVE:ATE)

Antibe Therapeutics logoAntibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. Its lead compound, ATB-346, combines hydrogen sulfide with naproxen, which is a non-steroidal anti-inflammatory drug (NSAID). The Company's other products include ATB-352, which is indicated for the treatment of severe acute pain, and ATB-340 is a Gastrointestinal (GI)-safe derivative of aspirin. The Company also offers regenerative medical devices, which include PentOS (CGX-283), CGX-227, CGX-443 and URIST (CGX-276), all of which target bone regeneration, and are indicated for oral and maxillofacial surgery.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: CVE:ATE
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: C$16.19 million
  • Outstanding Shares: 111,681,000
Average Prices:
  • 52 Week Range: C$0.11 - C$0.29
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: N/A
Sales & Book Value:
  • Annual Revenue: C$9.11 million
  • Price / Sales: 1.78
  • Book Value: C$0.05 per share
  • Price / Book: 3.09
Profitability:
  • EBIDTA: ($4,470,000.00)
Misc:
  • Average Volume: 210,468 shs.
 

Frequently Asked Questions for Antibe Therapeutics (CVE:ATE)

What is Antibe Therapeutics' stock symbol?

Antibe Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ATE."

When will Antibe Therapeutics make its next earnings announcement?

Antibe Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, July, 27th 2017. View Earnings Estimates for Antibe Therapeutics.

Who are some of Antibe Therapeutics' key competitors?

How do I buy Antibe Therapeutics stock?

Shares of Antibe Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How much does a share of Antibe Therapeutics stock cost?

One share of Antibe Therapeutics stock can currently be purchased for approximately C$0.15.

Analyst Ratings

Consensus Ratings for Antibe Therapeutics (CVE:ATE) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Antibe Therapeutics (CVE:ATE)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Antibe Therapeutics (CVE:ATE)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Antibe Therapeutics (CVE:ATE)
Current Year EPS Consensus Estimate: $-0.100 EPS

Dividends

Dividend History for Antibe Therapeutics (CVE:ATE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Antibe Therapeutics (CVE:ATE)
Insider Trades by Quarter for Antibe Therapeutics (CVE:ATE)
Insider Trades by Quarter for Antibe Therapeutics (CVE:ATE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/29/2016Scott Wilson CurtisInsiderBuy19,500C$0.13C$2,535.00
3/28/2016Scott Wilson CurtisInsiderBuy30,500C$0.13C$3,965.00
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Antibe Therapeutics (CVE:ATE)
Latest Headlines for Antibe Therapeutics (CVE:ATE)
Source:
DateHeadline
finance.yahoo.com logoResearch Reports Initiated on Healthcare Stocks: OrganiGram Holdings, Aphria, Antibe Therapeutics, and Emerald ... - Yahoo Finance
finance.yahoo.com - May 3 at 10:28 AM
businesswire.com logoAntibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic - Business Wire (press release)
www.businesswire.com - April 26 at 8:57 PM
businesswire.com logoAntibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic
www.businesswire.com - April 26 at 3:56 PM
finance.yahoo.com logoAntibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic - Yahoo Finance
finance.yahoo.com - April 26 at 10:03 AM
businesswire.com logoAntibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference - Business Wire (press release)
www.businesswire.com - April 25 at 3:39 PM
finance.yahoo.com logoAntibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference - Yahoo Finance
finance.yahoo.com - April 25 at 11:05 AM
businesswire.com logoAntibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference
www.businesswire.com - April 24 at 3:42 PM
businesswire.com logoAntibe Therapeutics Provides Update on Clinical Development Program for Its Lead Drug, ATB-346 - Business Wire (press release)
www.businesswire.com - April 18 at 3:37 PM
businesswire.com logoAntibe Therapeutics Provides Update on Clinical Development Program for Its Lead Drug, ATB-346
www.businesswire.com - April 18 at 9:58 AM
businesswire.com logoAntibe's Founder and Chief Scientific Officer to Receive Distinguished Lifetime Achievement Award in Research - Business Wire (press release)
www.businesswire.com - March 28 at 3:39 PM
businesswire.com logoAntibe’s Founder and Chief Scientific Officer to Receive Distinguished Lifetime Achievement Award in Research
www.businesswire.com - March 28 at 11:08 AM
businesswire.com logoAntibe Therapeutics Reports Q3 2017 Interim Financial and Operating Results
www.businesswire.com - March 1 at 8:41 PM
finance.yahoo.com logoIIROC Trading Resumption - ATE
finance.yahoo.com - February 24 at 6:12 PM
businesswire.com logoAntibe Therapeutics Enters into Regional Licensing Deal
www.businesswire.com - February 24 at 6:12 PM
finance.yahoo.com logoAntibe Therapeutics Enters into Regional Licensing Deal - Yahoo Finance
finance.yahoo.com - February 24 at 1:11 PM
businesswire.com logoAntibe Therapeutics Engages MKR Group for US Investor Relations - Business Wire (press release)
www.businesswire.com - February 22 at 11:22 AM
finance.yahoo.com logoAntibe Therapeutics Engages MKR Group for U.S. Investor Relations
finance.yahoo.com - February 21 at 9:46 AM
businesswire.com logoAntibe Therapeutics Announces the Launch of PentOS OI™ Max, Its Newest Bone Graft Substitute for Oral and ... - Business Wire (press release)
www.businesswire.com - January 31 at 8:53 PM
finance.yahoo.com logoAntibe Therapeutics Announces the Launch of PentOS OI™ Max, Its Newest Bone Graft Substitute for Oral and Maxillofacial Surgery
finance.yahoo.com - January 31 at 3:52 PM
businesswire.com logoAntibe Therapeutics Announces Change of Auditor to Ernst & Young
www.businesswire.com - January 19 at 2:19 AM
businesswire.com logoAntibe Therapeutics Completes Final Closing of Private Placement Bringing Total Proceeds to $2.7 Million
www.businesswire.com - December 22 at 2:44 AM
businesswire.com logoAntibe Therapeutics Completes Final Closing of Private Placement Bringing Total Proceeds to $2.7 Million - Business Wire (press release)
www.businesswire.com - December 21 at 9:44 PM
businesswire.com logoAntibe Therapeutics Raises $2.4 Million in First Tranche of Private Placement - Business Wire (press release)
www.businesswire.com - December 17 at 1:59 AM
businesswire.com logoAntibe Therapeutics Raises $2.4 Million in First Tranche of Private Placement
www.businesswire.com - December 16 at 3:56 PM
businesswire.com logoAntibe Therapeutics Reports Q2 2017 Interim Financial and Operating Results - Business Wire (press release)
www.businesswire.com - November 30 at 8:42 PM
businesswire.com logoAntibe Therapeutics Reports Q2 2017 Interim Financial and Operating Results
www.businesswire.com - November 30 at 9:21 AM
baystreet.ca logoResearch Reports Initiated on Healthcare Stocks OrganiGram Holdings, Aphria, Antibe Therapeutics, and biOasis Technologies
www.baystreet.ca - November 29 at 4:49 PM
businesswire.com logoAntibe Therapeutics Confirms Non-Addictive Properties for Its Second Pipeline Drug, ATB-352, a Potent, Non-Addictive Pain-Killer
www.businesswire.com - October 17 at 8:27 AM
businesswire.com logoAntibe Therapeutics Announces Launch of Strategic Growth Initiative in the U.S. Market for Dental Biologics
www.businesswire.com - October 11 at 3:41 PM
businesswire.com logoAntibe Therapeutics to Present at 2016 Rodman & Renshaw Global Investment Conference
www.businesswire.com - September 7 at 12:34 PM
businesswire.com logoAntibe Therapeutics Reports Q1 2017 Interim Financial and Operating Results
www.businesswire.com - August 30 at 3:37 PM
finance.yahoo.com logoAntibe Therapeutics Announces the Launch of Neomem® FlexPlus, a High-Performance Barrier Membrane for Oral Surgery
finance.yahoo.com - August 16 at 3:41 PM
businesswire.com logoAntibe Therapeutics Announces Successful Phase 2 Trial of ATB-346 in Osteoarthritis
www.businesswire.com - August 8 at 8:25 AM
finance.yahoo.com logoAntibe Therapeutics Reports 2016 Year-End Financial and Operating Results
finance.yahoo.com - July 29 at 9:05 PM
businesswire.com logoAntibe Therapeutics Announces the Appointment of New Board Member and Provides Update on Phase 2 Trial of ATB-346
www.businesswire.com - July 19 at 9:49 AM
finance.yahoo.com logoAntibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $1,455,000
finance.yahoo.com - June 22 at 8:46 PM
streetinsider.com logoAntibe Therapeutics Raises $968,500 in First Tranche of Non-Brokered Private Placement
www.streetinsider.com - June 10 at 9:28 PM
businesswire.com logoAntibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference
www.businesswire.com - May 30 at 10:50 AM
thestreet.com logoAntibe Therapeutics To Present At 2016 Bloom Burton & Co. Healthcare Investor Conference
www.thestreet.com - May 2 at 11:57 AM
businesswire.com logoAntibe Therapeutics Announces the Launch of PentOS OI™ Putty, a High-Quality Bone Graft Substitute for Oral and Maxillofacial Surgery
www.businesswire.com - April 18 at 11:28 AM
thestreet.com logoAntibe Therapeutics Announces Grant Of Stock Options
www.thestreet.com - March 10 at 10:03 AM
thestreet.com logoAntibe Therapeutics' ATB-346 Receives Approval For Phase 2 Clinical Trial In Osteoarthritis Patients
www.thestreet.com - March 7 at 9:59 AM
businesswire.com logoAntibe Therapeutics Receives Approval to Proceed to Phase 2 Clinical Trial
www.businesswire.com - March 5 at 9:38 AM

Social

Chart

Antibe Therapeutics (ATE) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff